<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref204">
 <label>[204]</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Gerson</surname>
   <given-names>JE</given-names>
  </string-name>, 
  <string-name>
   <surname>Farmer</surname>
   <given-names>KM</given-names>
  </string-name>, 
  <string-name>
   <surname>Henson</surname>
   <given-names>N</given-names>
  </string-name>, 
  <string-name>
   <surname>Castillo-Carranza</surname>
   <given-names>DL</given-names>
  </string-name>, 
  <string-name>
   <surname>Carretero Murillo</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Sengupta</surname>
   <given-names>U</given-names>
  </string-name>, 
  <string-name>
   <surname>Barrett</surname>
   <given-names>A</given-names>
  </string-name>, 
  <string-name>
   <surname>Kayed</surname>
   <given-names>R</given-names>
  </string-name> (
  <year>2018</year>) 
  <article-title>Tau oligomers mediate 
   <italic>Î±</italic>-synuclein toxicity and can be targeted by immunotherapy
  </article-title>. 
  <source>Mol Neurodegener</source>
  <volume>13</volume>, 
  <fpage>13</fpage>.
  <pub-id pub-id-type="pmid">29544548</pub-id>
 </mixed-citation>
</ref>
